CompletedNCT06709820Updated Apr 3, 2026

A Study of LY4060874 in Healthy Participants

A Phase 1 interventional study of LY4060874 and LY4060874 in Healthy Participants, sponsored by Eli Lilly and Company. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Phase: Phase 1
Study type: Interventional
Enrollment: 121
Allocation: Randomized
Ages: 18 Years to 65 Years
Sex: All

Study summary

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.

Study participation may last up to 22 weeks and up to approximately 18 study visits.

Conditions studied

Healthy Participants

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.

Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 65 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Are overtly healthy as determined by medical evaluation, including medical history and physical examination.
Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening.
To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion criteria

Exclusion Criteria:

Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.
Have hemoglobin A1c (HbA1c) > 6.4% or 46 millimoles/mole (mmol/mol) at screening.
Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.
Have had surgical treatment for obesity.
Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.

Study design

Phase: Phase 1
Primary purpose: Basic science
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Investigator)
Enrollment: 121 participants (actual)

Study arms

Experimental
LY4060874 (Part A Subcutaneous)
Single ascending dose of LY4060874 administered subcutaneously (SC).
Drug: LY4060874
Experimental
LY4060874 (Part A Intravenous)
Single ascending dose of LY4060874 administered intravenously (IV).
Drug: LY4060874
Experimental
LY4060874 (Part B)
Multiple ascending doses of LY4060874 administered SC.
Drug: LY4060874
Experimental
LY4060874 (Part B Chinese)
Multiple ascending doses of LY4060874 administered SC in Chinese participants.
Drug: LY4060874
Experimental
LY4060874 (Part C Japanese)
Multiple ascending doses of LY4060874 administered SC in Japanese participants.
Drug: LY4060874
Placebo comparator
Placebo (SC)
Placebo administered SC in Part A, B, and C.
Drug: Placebo
Placebo comparator
Placebo (IV)
Placebo administered IV in Part A.
Drug: Placebo

Interventions

DrugLY4060874
Administered SC
DrugLY4060874
Administered IV
DrugPlacebo
Administered SC
DrugPlacebo
Administered IV

What researchers measure

Primary outcomes

Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Number of participants with one or more TEAEs and SAEs.
Time frame: Baseline up to 22 Weeks

Secondary outcomes

Pharmacokinetics (PK): Area Under the Concentration Versus Time (AUC) of LY4060874
PK: Area Under the Concentration Versus Time (AUC) of LY4060874
Time frame: PK: Part A: Baseline up to 13 weeks; Part B and C: Baseline up to 18 weeks
PK: Maximum Observed Concentration of LY4060874
PK: Cmax of LY4060874
Time frame: PK: Part A: Baseline up to 13 weeks; Part B and C: Baseline up to 18 weeks

Study locations

2 sites

Fortrea, Inc.
Dallas, Texas 75247, United States
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06709820
Lead sponsor: Eli Lilly and Company
Responsible party: Sponsor
First posted: Nov 29, 2024
Start date: Dec 2, 2024
Primary completion: Feb 20, 2026
Completion: Feb 20, 2026
Last update: Apr 3, 2026

Study contacts

1-877-CTLILLY (1-877-285-4559) or 3176154559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

study director · Eli Lilly and Company

Oversight

Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Eli Lilly and Company

Start the discussion